Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization.
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Lenvatinib is an oral multikinase inhibitor that selectively inhibits vascular endothelial growth factor (VEGF) receptors 1 to 3 and other proangiogenic and oncogenic pathway-related receptor tyrosine kinases. To elucidate the origin of the potency of lenvatinib in VEGF receptor 2 (VEGFR2) inhibition, we conducted a kinetic interaction analysis of lenvatinib with VEGFR2 and X-ray analysis of the crystal structure of VEGFR2-lenvatinib complexes. Kinetic analysis revealed that lenvatinib had a rapid association rate constant and a relatively slow dissociation rate constant in complex with VEGFR2. Co-crystal structure analysis demonstrated that lenvatinib binds at its ATP mimetic quinoline moiety to the ATP binding site and to the neighboring region via a cyclopropane ring, adopting an Asp-Phe-Gly (DFG)-"in" conformation. These results suggest that lenvatinib is very distinct in its binding mode of interaction compared to the several approved VEGFR2 kinase inhibitors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [20]
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Rini, B. I., Escudier, B., Tomczak, P., Kaprin, A., Szczylik, C., Hutson, T. E., Michaelson, M. D., Gorbunova, V. A., Gore, M. E., Rusakov, I. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61613-9 · Cited by 1,840
Drug-target residence time and its implications for lead optimization
Copeland, R. A., Pompliano, D. L., & Meek, T. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2082 · Cited by 1,464
CH/? hydrogen bonds in crystals
Nishio, M. (2004) · CrystEngComm · doi:10.1039/b313104a · Cited by 1,422
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Research works printed but not linked: 1
- Schlumberger M., 2014, ASCO Meet. Abstr., 32, LBA6008
Cited by
Talele, T. T. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00472 · Cited by 1,023
FDA-approved small-molecule kinase inhibitors
Wu, P., Nielsen, T. E., & Clausen, M. H. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.04.005 · Cited by 1,013
Roskoski, R. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.10.021 · Cited by 886
Molecular targeted therapy for anticancer treatment
Min, H.-Y., & Lee, H.-Y. (2022) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00864-3 · Cited by 569
Kato, Y., Tabata, K., Kimura, T., Yachie-Kinoshita, A., Ozawa, Y., Yamada, K., Ito, J., Tachino, S., Hori, Y., Matsuki, M., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212513 · Cited by 460
Self-citationSmall-molecule kinase inhibitors: an analysis of FDA-approved drugs
Wu, P., Nielsen, T. E., & Clausen, M. H. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.008 · Cited by 457
Urea Derivatives in Modern Drug Discovery and Medicinal Chemistry
Ghosh, A. K., & Brindisi, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01541 · Cited by 401
Atropisomerism in Medicinal Chemistry: Challenges and Opportunities
Toenjes, S. T., & Gustafson, J. L. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0152 · Cited by 382
Fibroblast growth factor receptors as treatment targets in clinical oncology
Katoh, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0115-y · Cited by 352
Matsuki, M., Hoshi, T., Yamamoto, Y., Ikemori‐Kawada, M., Minoshima, Y., Funahashi, Y., & Matsui, J. (2018) · Cancer Medicine · doi:10.1002/cam4.1517 · Cited by 266
“Lenvatinib binds to the receptor tyrosine kinase VEGFR2 with Type V binding mode [28]; this may contribute to its high affinity and its selectivity for a small number of receptor tyrosine kinases.”
BackgroundSelf-citationSmall Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00963 · Cited by 265
Roskoski, R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.03.010 · Cited by 260
Ronchetti, R., Moroni, G., Carotti, A., Gioiello, A., & Camaioni, E. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00058f · Cited by 231
Allosteric small-molecule kinase inhibitors
Wu, P., Clausen, M. H., & Nielsen, T. E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.10.002 · Cited by 204
“, 2014; Lamba & Ghosh, 2012), and a few inhibitors with hybrid type I and II features (Okamoto et al., 2015), which has also been referred to as type 11⁄2 inhibitors (Zuccotto et al.”
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Lenvatinib in Management of Solid Tumors
Hao, Z., & Wang, P. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0407 · Cited by 132
“Lenvatinib binds at its ATP mimetic moiety to the ATP binding site and neighboring region of VEGFR2 in a unique way different from several other known VEGFR2 TKIs such as sorafenib and sunitinib [14].”
BackgroundStructure and function of vascular endothelial growth factor and its receptor system
Park, S. A., Jeong, M. S., Ha, K., & Jang, S. B. (2018) · BMB Reports · doi:10.5483/bmbrep.2018.51.2.233 · Cited by 125
“crystal structure of the catalytic kinase domain of VEGFR-2 was determined (33-36).”
BackgroundWirth, L. J., Tahara, M., Robinson, B. G., Francis, S. A., Brose, M. S., Habra, M. A., Newbold, K. L., Kiyota, N., Dutcus, C. E., Mathias, E. G., et al. (2018) · Cancer · doi:10.1002/cncr.31344 · Cited by 112
“The higher incidence of severe HTN with lenvatinib treatment compared with other agents may be due to its more potent inhibition of VEGFR2.(18) One possible mechanism of VEGFR inhibitor–induced HTN may involve the interruption of endothelial cell survival signaling, which can lead to apoptosis and capillary rarefactio…”
BackgroundLenvatinib: First Global Approval
Scott, L. J. (2015) · Drugs · doi:10.1007/s40265-015-0383-0 · Cited by 104
“Based on x-ray crystallography and kinetic interaction studies, lenvatinib binds to the adenosine 50-triphosphate binding site of VEGFR2 and to a neighbouring region via a cyclopropane ring and thereby inhibits tyrosine kinase activity and associated signalling pathways, with this binding differing from that of other…”
BackgroundRobinson, B. G., Schlumberger, M. J., Wirth, L. J., Dutcus, C. E., Song, J., Taylor, M. H., Kim, S., Krzyzanowska, M. K., Capdevila, J., Sherman, S. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3989 · Cited by 95
“4104 Robinson et al Tumor Size Changes Over Time With Lenvatinib J Clin Endocrinol Metab, November 2016, 101(11):4103–4109”
BackgroundInfluentialShahzadi, I., Zahoor, A. F., Tüzün, B., Mansha, A., Anjum, M. N., Rasul, A., Irfan, A., Kotwica-Mojzych, K., & Mojzych, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278027 · Cited by 95
“By using cell growth inhibition MTT assay as standard [41], cell viability was evaluated.”
MethodSana, S., Reddy, V. G., Bhandari, S., Reddy, T. S., Tokala, R., Sakla, A. P., Bhargava, S. K., & Shankaraiah, N. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112457 · Cited by 96
Martorana, A., Monica, G. L., & Lauria, A. (2020) · Molecules · doi:10.3390/molecules25184279 · Cited by 94
Fibroblast growth factors, old kids on the new block
Li, X., Wang, C., Xiao, J., McKeehan, W. L., & Wang, F. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.12.014 · Cited by 95
Zhao, W. H., Zheng, X., Tang, P. Y., Li, H., Liu, X., Zhong, J., & Tang, Y.-J. (2023) · Medicinal Research Reviews · doi:10.1002/med.21963 · Cited by 94
“In addition, sorafenib is a diaryl urea derivative and small molecule multi‐kinase inhibitor clinically available and licensed for marketing in hepatocellular sarcoma and renal cell carcinoma.(57) Taking these ideas into account, a series of thiourea substituted PAP derivatives (Figure 5, 8) were designed byTüre et al.”
BackgroundGaspar, N., Venkatramani, R., Hecker-Nolting, S., Melcon, S. G., Locatelli, F., Bautista, F., Longhi, A., Lervat, C., Entz-Werle, N., Casanova, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00387-9 · Cited by 89
Lenvantinib: A Tyrosine Kinase Inhibitor of VEGFR 1-3, FGFR 1-4, PDGFRα, KIT and RET
Zschäbitz, S., & Grüllich, C. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_13 · Cited by 94
Xu, Y., Yang, Q., Liu, T., Li, K., Liu, Y., Zhu, C., Zhang, Z., Li, L., Zhang, C., Xie, M., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.054 · Cited by 87
Abdel‐Mohsen, H. T., Abdullaziz, M. A., Kerdawy, A. M. E., Ragab, F. A. F., Flanagan, K. J., Mahmoud, A. E. E.-D., Ali, M. M., Diwani, H. I. E., & Senge, M. O. (2020) · Molecules · doi:10.3390/molecules25040770 · Cited by 83
“, sorafenib (I; PDB 4ASD) [26], regorafenib (II) and lenvatinib (III; 3WZD) [12], were found to share common pharmacophoric features, which are (1) a hinge region binding moiety ”head”, which is a heterocycle that occupies the adenine region in the ATP binding pocket with H bond donor and/or acceptor capabilities to i…”
BackgroundFinn, R. S., Kudo, M., Cheng, A., Wyrwicz, L. S., Ngan, R. K. C., Blanc, J., Baron, A. D., Vogel, A., Ikeda, M., Piscaglia, F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4219 · Cited by 86
“receptors 1–3, fibroblast growth factor (FGF) receptors 1–4, platelet-derived growth factor receptor-α (PDGFRα), KIT, and RET, with a distinct in vitro kinase inhibitory profile and kinase binding mode compared with sorafenib (1-5).”
Self-citationFogli, S., Porta, C., Re, M. D., Crucitta, S., Gianfilippo, G., Danesi, R., Rini, B. I., & Schmidinger, M. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101966 · Cited by 78
Une, N., Takano-Kasuya, M., Kitamura, N., Ohta, M., Inose, T., Kato, C., Nishimura, R., Tada, H., Miyagi, S., Ishida, T., et al. (2021) · Medical Oncology · doi:10.1007/s12032-021-01503-z · Cited by 82
“Since both sorafenib and lenvatinib are multi-target TKIs, they have different abilities to inhibit VEGFR, PDGFR, and fibroblast growth factor receptors (FGFR); in particular, the inhibitory effect of lenvatinib on VEGFR is higher than that of sorafenib [24, 25].”
BackgroundSalama, S. K., Mohamed, M. F., Darweesh, A. F., Elwahy, A. H. M., & Abdelhamid, I. A. (2017) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2017.01.009 · Cited by 76
Mou, L., Tian, X., Zhou, B., Zhan, Y., Chen, J., Lu, Y., Deng, J., Deng, Y., Wu, Z., Li, Q., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.752725 · Cited by 77
β-Caryophyllene Induces Apoptosis and Inhibits Angiogenesis in Colorectal Cancer Models
Dahham, S. S., Tabana, Y., Asif, M., Ahmed, M., Babu, D., Hassan, L. E. A., Ahamed, M. B. K., Sandai, D. A., Barakat, K., Siraki, A. G., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910550 · Cited by 82
“The ligand then extended to the lipophilic site (Site#0) through the 4-chloro-3(trifluoromethyl)phenyl group [25].”
BackgroundAlanazi, M. M., Elkady, H., Alsaif, N. A., Obaidullah, A. J., Alkahtani, H. M., Alanazi, M. M., Alharbi, M. A., Eissa, I. H., & Dahab, M. A. (2021) · RSC Advances · doi:10.1039/d1ra05925d · Cited by 73
Faraji, A., Bakhshaiesh, T. O., Hasanvand, Z., Motahari, R., Nazeri, E., Boshagh, M. A., Firoozpour, L., Mehrabi, H., Khalaj, A., Esmaeili, R., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112942 · Cited by 72
Mansour, G. H., El‐Magd, M. A., Mahfouz, D. H., Abdelhamid, I. A., Mohamed, M. F., Ibrahim, N. S., Wahab, A. H. A. A., & Elzayat, E. M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105329 · Cited by 73
Marzouk, A. A. E., Abdel‐Aziz, S. A., Abdelrahman, K. S., Wanas, A. S., Gouda, A. M., Youssif, B. G. M., & Abdel‐Aziz, M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104090 · Cited by 63
Tantawy, M. A., Sroor, F. M., Mohamed, M. F., El-Naggar, M. E., Saleh, F. M., Hassaneen, H. M., & Abdelhamid, I. A. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666191024121116 · Cited by 62
Urea-based anticancer agents. Exploring 100-years of research with an eye to the future
Listro, R., Rossino, G., Piaggi, F., Sonekan, F. F., Rossi, D., Linciano, P., & Collina, S. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.995351 · Cited by 61
“Notwithstanding this difference, the crystallographic structure of lenvatinib with VEGFR-2 demonstrated an overall comparable binding mode to sorafenib with BRAF (PDB ID: 3WZE) (Okamoto et al., 2015).”
BackgroundInfluentialGhith, A., Youssef, K. M., Ismail, N. S. M., & Abouzid, K. A. M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.008 · Cited by 59
Resistance of Lenvatinib in Hepatocellular Carcinoma
Xu, Q., Huang, D., Guo, J., & Zhao, J. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220428111327 · Cited by 61
Ringing medicinal chemistry: The importance of 3-membered rings in drug discovery
Uthumange, S. S., Liew, A. J. H., Wezen, X. C., & Yeong, K. Y. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117980 · Cited by 61
Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo
Ogasawara, S., Mihara, Y., Kondo, R., Kusano, H., Akiba, J., & Yano, H. (2019) · Anticancer Research · doi:10.21873/anticanres.13802 · Cited by 62
Makker, V., Aghajanian, C. A., Cohn, A. L., Romeo, M., Bratos, R., Brose, M. S., Messing, M. J., Dutta, L., Dutcus, C. E., Huang, J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01021 · Cited by 58
Elsayed, N. M. Y., Serya, R. A. T., Tolba, M. F., Ahmed, M., Barakat, K., Ella, D. A. A. E., & Abouzid, K. A. M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.10.071 · Cited by 56
New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
Mossenta, M., Busato, D., Baboçi, L., Cintio, F. D., Toffoli, G., & Bo, M. D. (2019) · Cancers · doi:10.3390/cancers11081086 · Cited by 56
“A structural study demonstrated that lenvatinib inhibits its targets interacting with the ATP binding site [50].”
BackgroundA guide to enzyme kinetics in early drug discovery
Srinivasan, B. (2022) · FEBS Journal · doi:10.1111/febs.16404 · Cited by 55
Pareto optimization to accelerate multi-objective virtual screening
Fromer, J. C., Graff, D., & Coley, C. W. (2024) · Digital Discovery · doi:10.1039/d3dd00227f · Cited by 60
Recent advances of RAF (rapidly accelerated fibrosarcoma) inhibitors as anti-cancer agents
Ammar, U. M., Abdel‐Maksoud, M. S., & Oh, C. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.005 · Cited by 55
Saleh, N. M., Abdel‐Rahman, A. A. ‐., Omar, A. M., Khalifa, M. M., & El‐Adl, K. (2021) · Archiv der Pharmazie · doi:10.1002/ardp.202100085 · Cited by 53
Wang, Y., Wan, S., Li, Z., Fu, Y., Wang, G., Zhang, J., & Wu, X. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.05.054 · Cited by 52
Sobhy, M. K., Mowafy, S., Lasheen, D. S., Farag, N. A., & Abouzid, K. A. M. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102988 · Cited by 52
“Hydrophobic interaction with the kinase front pocket complements the hydrogen bonding with the hinge region, increasing the residence time [8], which is a key factor in improving potency in vivo and enhancing the correlation between the in vitro and in vivo efficacy of drugs [18].”
BackgroundMethodInfluentialMolecular mechanisms of resistance to kinase inhibitors in thyroid cancers
Hofmann, M.-C. C., Kunnimalaiyaan, M., Wang, J. R., Busaidy, N. L., Sherman, S. I., Lai, S. Y., Zafereo, M., & Cabanillas, M. E. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0129 · Cited by 53
Mahmoud, M. A., Mohammed, A. F., Salem, O. I. A., Rabea, S. M., & Youssif, B. G. M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135165 · Cited by 49
Aromatic Rings as Molecular Determinants for the Molecular Recognition of Protein Kinase Inhibitors
Zhu, Y., Alqahtani, S. M., & Hu, X. (2021) · Molecules · doi:10.3390/molecules26061776 · Cited by 48
“Figure 5 shows modes of non-bonde int rmolecular interactions between lenvatinib and its int racting residues in vascular endothelial growth factor receptor 2 [51].”
BackgroundInfluentialFleeman, N., Houten, R., Bagust, A., Richardson, M., Beale, S., Boland, A., Dundar, Y., Greenhalgh, J., Hounsome, J. C., Duarte, R. V., et al. (2020) · Health Technology Assessment · doi:10.3310/hta24020 · Cited by 47
Rbaa, M., Haida, S., Tüzün, B., Hichar, A., Anouar, E. H., Kribii, A., Lakhrissi, Y., Hadda, T. B., Zarrouk, A. M., Lakhrissi, B., et al. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.132688 · Cited by 45
Hadi, S. R. A. E., Lasheen, D. S., Soliman, D. H., Elrazaz, E. Z., & Abouzid, K. A. M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103961 · Cited by 45
Elrazaz, E. Z., Serya, R. A. T., Ismail, N. S. M., Albohy, A., Ella, D. A. A. E., & Abouzid, K. A. M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105019 · Cited by 44
Rbaa, M., Oubihi, A., Hajji, H., Tüzün, B., Hichar, A., Anouar, E. H., Berdimurodov, E. T., Ajana, M. A., Zarrouk, A. M., & Lakhrissi, B. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130934 · Cited by 44
Saha, D., Ryan, K. R., Lakkaniga, N. R., Acharya, B., Garcia, N. G., Smith, E. L., & Frett, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c02167 · Cited by 45
Majumdar, D., Philip, J. E., Tüzün, B., & Roy, S. (2023) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2023.111057 · Cited by 42
Abdel‐Mohsen, H. T., Ibrahim, M. A., Nageeb, A. M., & Kerdawy, A. M. E. (2024) · BMC Chemistry · doi:10.1186/s13065-024-01135-0 · Cited by 42
Zhao, Z., Song, J., Zhang, D., Wu, F., Tu, J., & Ji, J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118642 · Cited by 43
Miyano, S. W., Yamamoto, Y., Kodama, K., Miyajima, Y., Mikamoto, M., Nakagawa, T., Kuramochi, H., Funasaka, S., Nagao, S., Sugi, N. H., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0261 · Cited by 44
“These data suggest that the interaction of E7090 with FGFR1 possesses unique kinetics among selective FGFR inhibitors, similar to that of type V inhibitors (23).”
BackgroundMethodSelf-citationLenvatinib as a therapy for unresectable hepatocellular carcinoma
Spallanzani, A., Orsi, G., Andrikou, K., Gelsomino, F., Rimini, M., Riggi, L., & Cascinu, S. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1524297 · Cited by 42
Satheeshkumar, R., Prabha, K., Vennila, K. N., Sayın, K., Güney, E., Kaminsky, W., & Acevedo, R. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133552 · Cited by 41
Recent advances in multitarget-directed ligands via in silico drug discovery
Krishnaiah, M., Yada, B., Kumari, S., McHale, C. C., Pal, D., & Durden, D. L. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103904 · Cited by 44
Lenvatinib: A Review in Refractory Thyroid Cancer
Frampton, J. E. (2016) · Targeted Oncology · doi:10.1007/s11523-015-0416-3 · Cited by 45
“approved VEGFR2 kinase inhibitors [27].”
Lenvatinib induces early tumor shrinkage in patients with advanced thyroid carcinoma
Masaki, C., Sugino, K., Saito, N., Saito, Y., Tanaka, T., Ogimi, Y., Maeda, T., Osaku, T., Akaishi, J., Hames, K. Y., et al. (2017) · Endocrine Journal · doi:10.1507/endocrj.ej17-0104 · Cited by 39
Türe, A., Kahraman, D., Çetin-Atalay, R., Helvacıoğlu, S., Charehsaz, M., & Küçükgüzel, İ. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.12.003 · Cited by 38
Synthesis and evaluation of new thiourea derivatives as antitumor and antiangiogenic agents
Bai, W., Ji, J., Huang, Q., & Wei, W. (2020) · Tetrahedron Letters · doi:10.1016/j.tetlet.2020.152366 · Cited by 40
Faraji, A., Motahari, R., Hasanvand, Z., Bakhshaiesh, T. O., Toolabi, M., Moghimi, S., Firoozpour, L., Boshagh, M. A., Rahmani, R., Ketabforoosh, S. H. M. E., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104553 · Cited by 37
Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105660 · Cited by 37
Wang, Y., Peng, C., Wang, G., Xu, Z., Luo, Y., Wang, J., & Zhu, W. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13493 · Cited by 37
“These results are in good agreement with the experimental data (Okamoto et al., 2015), where the koff of SOR, LEN, and SUN are 2.”
BackgroundResultMultimodale Therapie des hepatozellulären Karzinoms
Kirstein, M. M., & Wirth, T. C. (2020) · Der Internist · doi:10.1007/s00108-019-00722-x · Cited by 42
El‐Mageed, M. M. A. A., Eissa, A. A. M., Farag, A. E.-S., & Osman, E. E. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105336 · Cited by 35
Khaled, N. A., Ahmed, N. S. I., Abdelazem, A. Z., Mohamed, N. A., El-Sayed, A. F., & Ahmed, S. A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135753 · Cited by 33
Small-molecule-based targeted therapy in liver cancer
Ming, Y., Gong, Y., Fu, X., Ouyang, X., Peng, Y., & Pu, W. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.08.001 · Cited by 32
Furuto, Y., Hashimoto, H., Namikawa, A., Outi, H., Takahashi, H., Horiuti, H., Honda, K., & Shibuya, Y. (2018) · BMC Nephrology · doi:10.1186/s12882-018-1074-3 · Cited by 31
Sarkı, G., Tüzün, B., Ünlüer, D., & Kantekın, H. (2022) · Inorganica Chimica Acta · doi:10.1016/j.ica.2022.121113 · Cited by 31
Recent developments in small molecule therapies for renal cell carcinoma
Song, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.007 · Cited by 31
Overview of Current Type I/II Kinase Inhibitors
Zhao, Z., & Bourne, P. E. (2020) · Springer eBooks · doi:10.1007/978-3-030-48283-1_2 · Cited by 34
The Targeted Therapies for Osteosarcoma via Six Major Pathways
Wang, S., Ren, Q., Li, G., Zhao, X., Zhao, X., & Zhang, Z. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230821142839 · Cited by 35
Albertí‐Valls, M., Olave, S., Olomí, A., Macià, A., & Eritja, N. (2024) · Cancers · doi:10.3390/cancers16233918 · Cited by 30
Sidhom, P. A., El-Bastawissy, E. A., Salama, A., & El-Moselhy, T. F. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105054 · Cited by 29
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma
Gaspar, N., Hung, G.-Y., Strauss, S. J., Campbell-Hewson, Q., Dela Cruz, F. S., Glade Bender, J. L., Koh, K.-N., Whittle, S. B., Chan, G. C.-F., Gerber, N. U., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.4381 · Cited by 28
Kiyota, N., Tahara, M., Robinson, B. G., Schlumberger, M. J., Sherman, S. I., Leboulleux, S., Lee, E. K., Suzuki, T., Ren, M., Fushimi, K., et al. (2022) · Cancer · doi:10.1002/cncr.34181 · Cited by 30
Zhang, W., Feng, L.-J., Teng, F., Li, Y., Zhang, X., & Ran, Y.-G. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1734450 · Cited by 27
“The higher incidence of proteinuria events with lenvatinib treatment compared with other agents may be due to its more potent inhibition of VEGFR 1–3 based on 50% inhibitory concentrations (IC50) of lenvatinib [36,37].”
BackgroundYavuz, S. Ç., Akkoç, S., Tüzün, B., Şahın, O., & Sarıpınar, E. (2021) · Synthetic Communications · doi:10.1080/00397911.2021.1922920 · Cited by 27
Sroor, F. M., Abdelhakim, H. K., Abdelrehim, S. M., Mahrous, K. F., El-Sayed, A. F., & Abdelhamid, I. A. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140001 · Cited by 27
Inherent formulation issues of kinase inhibitors
Herbrink, M., Schellens, J. H. M., Beijnen, J. H., & Nuijen, B. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.08.036 · Cited by 29
Kinase-Centric Computational Drug Development
Kooistra, A. J., & Volkamer, A. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.001 · Cited by 29
Wei, X., Zhang, T., Yao, Y., Zeng, S., Li, M., Xiang, H., Zhao, C., Cao, G., Li, M., Wan, R., et al. (2017) · Experimental Eye Research · doi:10.1016/j.exer.2017.12.009 · Cited by 27
Budolfsen, C., Faber, J., Grimm, D. G., Krüger, M., Bauer, J. W., Wehland, M., Infanger, M., & Magnusson, N. E. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190130165810 · Cited by 28
Han, Y., Zhi, W., Xu, F., Zhang, C., Huang, X., & Luo, J. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i19.2415 · Cited by 28
In Silico and In Vitro Antiproliferative Activity Assessment of New Schiff Bases
Kökbudak, Z., Akkoç, S., Karataş, H., Tüzün, B., & Aslan, H. G. (2022) · ChemistrySelect · doi:10.1002/slct.202103679 · Cited by 26
Fouad, M. A., Osman, A. A., Abdelhamid, N. M., Rashad, M. W., Nabawy, A. Y., & Kerdawy, A. M. E. (2024) · BMC Chemistry · doi:10.1186/s13065-024-01130-5 · Cited by 25
“The retrieved and prepared protein structures co-crystallized with various inhibitors for each protein kinase VEGFR2 and FAK (VEGFR2 PDB IDs: 4ASE, 4ASD, 2QU6, 3VHE, 3EWH, 3VNT, 3WZD, and 6XVK. FAK PDB IDs: 4KAO and 4K9Y) [47, 60, 61, 67–71] were first aligned separately.”
BackgroundMethodInfluential
Metadata
- Authors
- Okamoto, K., Ikemori-Kawada, M., Jestel, A., von König, K., Funahashi, Y., Matsushima, T., Tsuruoka, A., Inoue, A., & Matsui, J.
- Affiliations
- Eisai (Japan) (JP)
- Eisai Co., Ltd, Tsukuba, Ibaraki 300-2635, Japan
- Proteros Biostructures GmbH, Planegg-Martinsried, Germany
- Eisai (United States) (US)
- Corresponding author
- Matsui, Junji
- Venue
- ACS Medicinal Chemistry Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2014-11-20
- Volume
- 6
- Issue
- 1
- Pages
- 89-94
- ISSN
- 1948-5875 (ISSN-L)
- PMC
- PMC4291723
- OpenAlex
- W1976262446
- Cited by
- 285
- References
- 28
- Citations by year
- 2026: 32 · 2025: 29 · 2024: 31 · 2023: 27 · 2022: 30 · 2021: 40 · 2020: 24 · 2019: 23 · 2018: 19 · 2017: 12 · 2016: 11 · 2015: 7
- FWCI
- 4.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- ACS Medicinal Chemistry Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- lenvatinib, VEGFR2, multikinase inhibitor, ATP binding site, binding kinetics, crystal structure, receptor tyrosine kinase inhibition, VEGF receptor inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.